Key Words: hypertension, genetic Ⅲ receptors, dopamine Ⅲ dopamine Ⅲ hypertension, essential Ⅲ phosphatase E ssential hypertension is a multifactorial disorder thought to arise from the interactions of environmental factors with multiple genes. 1,2 Defective regulation of nerve activity, vascular reactivity, endocrine function, and ion transport in genetic hypertension has been linked to abnormalities in signal transduction. 1-3 Dopamine synthesized by renal proximal tubule cells (RPTC) plays an important paracrine/ autocrine role in the regulation of renal function during volume expansion. 3-5 Dopamine, through different dopamine receptor subtypes, regulates cardiovascular functions by actions on the central and peripheral nervous systems, vascular smooth muscle, and adrenal glands, heart, and kidney. 3 Abnormal regulation of cardiovascular function by various dopamine receptor subtypes has been implicated in the pathogenesis of genetic hypertension. 2, 3, 6, 7 In genetic hypertension, the D 1 dopamine receptor, a G-protein-coupled receptor (GPCR) in renal proximal tubules, is desensitized, serine-hyperphosphorylated, and uncoupled from its G protein/effector complex. 2, 8, 9 The functional status of GPCR is determined by the phosphorylation state, a dynamic process controlled by protein kinases and phosphatases. 10, 11 Receptor desensitization occurs after receptor phosphorylation and internalization. 10, 11 In contrast, receptor resensitization requires receptor dephosphorylation, a process mediated by a plasma membrane-associated form of protein phosphatase, a GPCR phosphatase (GRP). 11,12 GPCR resensitization requires protein phosphatase 2A (PP 2A ) activity because okadaic acid, an inhibitor of PP 2A activity, prevents receptor resensitization. 13 Moreover, when phosphorylated receptors translocate from plasma membrane to cytoplasmic vesicles, they become physically associated with PP 2A . 12, 14 Because PP 2A activity is involved in the dephosphorylation and resensitization of GPCR, it is possible that aberrant D 1 receptor regulation of PP 2A activity may be involved in the desensitization of this GPCR in genetic hypertension. PP 2A is a heterotrimeric protein serine/threonine phosphatase; the holoenzyme consists of a 36-kDa catalytic C subunit, a 65-kDa structural A subunit, and a variable regulatory B subunit. 15 Both the A and C subunits exist as 2 isoforms (␣ and ␤), whereas there are 3 families of B subunits: B or PR55,
ssential hypertension is a multifactorial disorder thought to arise from the interactions of environmental factors with multiple genes. 1, 2 Defective regulation of nerve activity, vascular reactivity, endocrine function, and ion transport in genetic hypertension has been linked to abnormalities in signal transduction. [1] [2] [3] Dopamine synthesized by renal proximal tubule cells (RPTC) plays an important paracrine/ autocrine role in the regulation of renal function during volume expansion. [3] [4] [5] Dopamine, through different dopamine receptor subtypes, regulates cardiovascular functions by actions on the central and peripheral nervous systems, vascular smooth muscle, and adrenal glands, heart, and kidney. 3 Abnormal regulation of cardiovascular function by various dopamine receptor subtypes has been implicated in the pathogenesis of genetic hypertension. 2, 3, 6, 7 In genetic hypertension, the D 1 dopamine receptor, a G-protein-coupled receptor (GPCR) in renal proximal tubules, is desensitized, serine-hyperphosphorylated, and uncoupled from its G protein/effector complex. 2, 8, 9 The functional status of GPCR is determined by the phosphorylation state, a dynamic process controlled by protein kinases and phosphatases. 10, 11 Receptor desensitization occurs after receptor phosphorylation and internalization. 10, 11 In contrast, receptor resensitization requires receptor dephosphorylation, a process mediated by a plasma membrane-associated form of protein phosphatase, a GPCR phosphatase (GRP). 11, 12 GPCR resensitization requires protein phosphatase 2A (PP 2A ) activity because okadaic acid, an inhibitor of PP 2A activity, prevents receptor resensitization. 13 Moreover, when phosphorylated receptors translocate from plasma membrane to cytoplasmic vesicles, they become physically associated with PP 2A . 12, 14 Because PP 2A activity is involved in the dephosphorylation and resensitization of GPCR, it is possible that aberrant D 1 receptor regulation of PP 2A activity may be involved in the desensitization of this GPCR in genetic hypertension. PP 2A is a heterotrimeric protein serine/threonine phosphatase; the holoenzyme consists of a 36-kDa catalytic C subunit, a 65-kDa structural A subunit, and a variable regulatory B subunit. 15 Both the A and C subunits exist as 2 isoforms (␣ and ␤), whereas there are 3 families of B subunits: B or PR55, BЈ or B56, and BЈЈ or PR72. 16 B56 is a new gene family that encodes B56␣, ␤, ␥, ␦, and ⑀ proteins. 17 The B56␤ and ␦ subunits are found predominantly in brain tissue, the B56␣ and ␥ subunits are most abundant in heart and muscle, and the ⑀ subunit is expressed mainly in the testis, lung, and brain. [17] [18] [19] [20] Of the B56 isoforms, B56␣ appears to be the most abundantly expressed subunit in the kidney. 17, 19, 21 PP 2A activity and protein levels were examined in renal cortical tubules from spontaneously hypertensive rats (SHR) and their normotensive controls, Wistar-Kyoto rats (WKY). To eliminate any confounding influence of dopamine produced by renal proximal tubules from circulating L-dihydroxyphenylalanine (L-DOPA), studies were also performed in immortalized renal proximal tubule cells (RPTC) 22 ; RPTC cannot synthesize dopamine in the absence of L-DOPA. 23 
Renal Cortical Membranes
Adult male WKY (body weight 375Ϯ43 g, mean arterial pressure [MAP] 98Ϯ3 mm Hg, nϭ4) and SHR (body weight 307Ϯ33 g, MAP 161Ϯ3 mm Hg, nϭ4) (Taconic Farms Inc), maintained on standard rat chow until the night before the experiment, were anesthetized with pentobarbital (50 mg/kg body wt IP) and tracheotomized (PE-240). MAP was monitored with Cardiomax II (Columbus Instruments). After a 30-minute equilibration period, saline or fenoldopam in saline (1 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) was infused (1.2 mL/h) into the right renal artery through the right suprarenal artery for 10 or 30 minutes. 25 The renal cortical cytosol and membrane fractions were prepared in TE buffer (mmol/L, 10 Tris-Cl, pH 7.4, 2 EDTA) and TBST buffer (mmol/L, 10 Tris-Cl, pH 7.4, 150 NaCl, 2 EDTA, 0.5% Triton X-100) as described previously with modification. 26 All buffers contained protease inhibitors (mmol/L): 5 DTT, 2 EDTA, and 1 pofabloc and 10 g/mL each of leupeptin and aprotinin.
Preparation of Brush Border Membranes
Brush border membranes (BBM) (100 g/sample), prepared by MnCl 2 precipitation and differential centrifugation, 27 were treated with fenoldopam (5 mol/L) or vehicle (saline) for 30 minutes at room temperature. The BBM were pelleted by centrifugation for 5 minutes, suspended in Laemmli buffer, and boiled for 5 minutes before immunoblotting.
Immortalized RPTC and Subcellular Fractions
Immortalized RPTC were maintained in DMEM/F12 supplemented with 5% fetal bovine serum, epidermal growth factor (10 ng/mL), insulin, transferrin, and selenium (5 g/mL each) at 37°C in humidified 5% CO 2 /95% air. 22 The cells were incubated for 1 hour in serum-free DMEM/F12 medium before agonist stimulation with the D 1 -like agonist fenoldopam (5 mol/L). The cells were washed 3 times with TBS and disrupted by Dounce homogenizer or a syringe with a 27-gauge needle in TE buffer. The cell lysates were centrifuged at 2000 rpm for 5 minutes to remove the nuclear fraction. The supernatants were centrifuged at 14 000 rpm for 20 minutes and the resulting supernatant was taken to represent cytosol. The pellets were extracted for 30 minutes on ice with TBST lysis to obtain the membrane fractions. 26 All experiments were carried out at 4°C in the presence of protease inhibitors described above. Protein concentrations were determined by the Bradford method.
PP 2A Activity Assay
PP 2A activity was measured after immunoprecipitation with anti-PP 2A catalytic subunit antibody, according to Gupta et al 28 with modifications. The cytosol and membrane preparations were subjected to immunoprecipitation carried out in triplicate (see below). The immune complexes with the protein G beads were initially washed twice with TBS buffer and finally washed with PP 2A assay buffer (in mmol/L, 20 MOPS, pH 7.5, 60 2-mercaptoethanol, 100 NaCl, 0.1 mg/mL serum albumin). Immunoprecipitates with mouse IgG served as negative control. The immunoprecipitates were subjected to PP 2A assay with a nonradioactive assay kit. In brief, the immune complexes containing PP 2A were incubated for 20 minutes at 30°C in 30 L of assay buffer containing 200 mol/L of phosphopeptide (KRpTIRR). The reactions were terminated by putting the tubes on ice and immediately centrifuging at 8000 rpm for 1 minute. The supernatants (25 L/well) were pipetted into 96-well microtiter plates containing malachite green solution (100 L/well). The absorbance was measured at optical density of 630 nm after 15 minutes of development time. PP 2A specific activity was expressed as pmol/min per milligram of protein. The lower limit of detection was 20 pmol of Pi (released phosphate from the phosphopeptide).
Immunoprecipitation and Immunoblotting
The immunoprecipitation for the PP 2A assay was performed by incubation of 50 to 200 g of protein with 2 g of PP 2A -C monoclonal antibody and protein G beads in TBS buffer with rocking for 2 hours in a cold room. For immunoblotting, 50 to 100 g of protein was loaded onto polyacrylamide gel. The amount of protein transferred onto the nitrocellulose membrane was verified by Ponceau-S stain. Immunoblotting and quantification of the immunoblots were performed as described previously with Quantiscan. 26 The results were expressed as density units (DU).
Statistical Analysis
The data are expressed as meanϮSEM. Comparison within groups was made by ANOVA for repeated measures (or paired t test when only 2 groups were compared), and comparison among groups (or t test when only 2 groups were compared) was made by ANOVA with Scheffe's or Duncan's test. Corresponding periods between 2 different groups were analyzed by independent t test. A value of PϽ0.05 was considered significant.
Results
D 1 -like receptors are expressed to a greater extent in the renal cortex (proximal tubule, distal tubule, cortical collecting) and to a lesser extent in the medulla (medullary thick ascending limb of Henle. 3 Therefore, PP 2A expression and activity were studied in the renal cortex.
In Vivo Studies

PP 2A Expression
Basal Expression PP 2A A␣, the structural subunit, PP 2A -C, the catalytic subunit, and PP 2A -B56␣, the regulatory subunit, were expressed to a similar extent in renal cortical tubules of WKY and SHR (Figure 1 ). In agreement with data obtained with the use of tissues other than the kidney, PP 2A was more abundant in the cytosol than in the particulate fraction. 29 (Figure 2 ).
PP 2A Activity
The majority of PP 2A are heterotrimers that contain a variable regulatory B subunit bound to the A-C dimer. 16, [33] [34] [35] To determine specific PP 2A activity, we measured PP 2A activity in immunoprecipitates of the specific monoclonal anti-PP 2A -C subunit antibody. 28, 36 The protein phosphatase activity on the immune complex was predominantly PP 2A , because the A subunit and B56␣ of PP 2A were also coimmunoprecipitated with anti-C (data not shown), and the activity was inhibited dose-dependently by a PP 2A inhibitor, okadaic acid (Ϸ50%, data not shown). 
Basal Activity
In Vitro Studies
We have reported that D 1 -like receptor function in immortalized RPTC is similar to that in renal proximal tubules freshly obtained from WKY. 37, 38 The uncoupling of the D 1 -like receptor in renal proximal tubules in SHR persists in immortalized RPTC from SHR. 9 17.1Ϯ3.8 DU, nϭ4) ( Figure 3A ) (convert to 100% as the sum of cytosol and membrane).
Effect of D 1 -Like Agonist
In membranes from immortalized RPTC of WKY, the D 1 -like agonist fenoldopam (5 mol/L) increased PP 2A -B56␣ protein levels with time ( Figure 3A) . In cytosol of immortalized RPTC of WKY, fenoldopam decreased PP2A-B56␣ protein levels in a manner reciprocal with that seen in membranes. The increase in PP 2A -B56␣ expression in the membranes caused by 5 mol/L fenoldopam (80Ϯ23% over basal, PϽ0.05 ANOVA, Duncan's test) was partially blocked by 5 mol/L SCH23390 (47Ϯ29% over basal, PϾ0.05 ANOVA, Duncan's test), which, by itself, had no effect (29Ϯ23% over basal, PϾ0.05 ANOVA, Duncan's test). In contrast to the WKY rats, fenoldopam produced no change in PP 2A -B56␣ expression in either membrane or cytosol in immortalized RPTC of SHR (data not shown).
PP 2A Activity
Basal Activity
In the absence of endogenous dopamine, basal PP 2A activity (pmol/min per milligram of protein) in the membrane was markedly higher in immortalized RPTC of SHR (540Ϯ46, nϭ3) than in immortalized RPTC of WKY (233Ϯ21, nϭ3) (PϽ0.05, t test). However, PP 2A activity in cytosol was not different between SHR (496Ϯ36, nϭ3) and WKY (473Ϯ95, nϭ4).
Effect of D 1 -Like Agonist
In immortalized RPTC membranes from WKY, fenoldopam (5 mol/L) increased PP 2A activity (pmol/min per milligram of protein) with time, peaking at 30 minutes to 278Ϯ21 (PϽ0.05 versus basal activity, nϭ4); no effect was noted in cytosol ( Figure 3B ). In contrast, in the immortalized RPTC from SHR, fenoldopam decreased PP 2A activity in both cytosol and membrane fractions in a time-dependent manner ( Figure 3B ), in agreement with studies that used renal cortical tubules. The maximum decrease occurred at 30 minutes down to 327Ϯ63 in membrane (nϭ3) and 428Ϯ30 in cytosol (nϭ3) (PϽ0.05 versus basal activity).
Effect of D 1 -Like Antagonist SCH23390
To determine if the effect of the D 1 agonist fenoldopam is mediated by the occupation of the D 1 receptor, studies were performed in the presence of the D 1 -like antagonist SCH23390 (5 mol/L), a neutral antagonist. Fenoldopam (5 mol/L, 30 minutes ( Figure 3C ) increased PP 2A activity in membrane of WKY (22.6Ϯ4.4% from basal) (PϽ0.05, nϭ4), which was blocked by SCH23390 (9.3Ϯ3.8% from basal, nϭ4); SCH23390, by itself (3.9Ϯ5.7% from basal, nϭ5), had no effect on PP 2A activity. Fenoldopam decreased the activity in cytosol of SHR (Ϫ18.0Ϯ2.8% versus basal, nϭ4, PϽ0.05), an effect that was blocked by SCH23390 (Ϫ10.4Ϯ4.3% from basal, nϭ4 PϾ0.05); SCH23390, by itself, had no effect on PP 2A activity (Ϫ8.7Ϯ3.6% from basal, nϭ4 to 5, PϾ0.05).
Discussion
Several studies have shown that GRP plays a role in receptor dephosphorylation that is important in receptor resensitiza- tion. [12] [13] [14] 36, 39, 40 A high level of receptor phosphatase activity was reported to be associated with sequestered vesicular membranes, capable of dephosphorylating GRK-phosphorylated ␤-adrenergic receptors. 41 Moreover, the resensitization of GPCR was inhibited by phosphatase inhibitors. [12] [13] [14] 36, 39, 40 GRP has been identified as a member of the family of PP 2A . 12 PP 2A is generally considered as a cytosolic protein. 33 However, PP 2A is also expressed in cell particulate fractions. 12 We also found that PP 2A protein level were much higher in the cytosol than in membranes from renal cortex and immortalized RPTC in both WKY and SHR. However, PP 2A specific activity was not different in cytosol and membrane fractions.
In addition to GPCR resensitization, PP 2A is involved in a broad range of cellular processes, including signal transduction, intermediary metabolism, transcriptional regulation and control of DNA replication, and mitosis. 16, 36, 39, 40, 42, 43 The diversity of PP 2A function is conferred by a variety of targeting/regulatory subunits. Each of the B subunits consists of numerous isoforms and splice variants. 16, 33, 42 The PP 2A regulatory B subunits have been found to have a number of functions, including targeting to distinct intracellular locations, determining substrate and tissue specificity, and acting as receptors of second messengers. 17, 30 Most of the B56 family members are phosphoproteins, and different isoforms have different targeting functions. 17, 30 The function of PP 2A -B56␣ in hypertension remains to be determined. However, the failure of the D 1 -like agonist to translocate PP 2A activity from cytosol to membrane in SHR may explain, in part, the "hyper"-serine-phosphorylated D 1 receptor in renal membranes in genetic hypertension. 8, 9 The finding of a difference in PP 2A activity between WKY and SHR in RPTC, where dopamine is absent, but not in renal cortical tubules, where dopamine is present, suggests that dopamine may tonically inhibit the PP 2A activity, especially in the cytosol. Because PP 2A -B56␣ is important in the targeting of the PP 2A holoenzyme, a defect in B56␣ function could be involved in the pathogenesis of genetic hypertension. The important finding in our study is the remarkable difference in D 1 -like receptorassociated PP 2A activity in RPTC membranes between WKY and SHR. The D 1 -like agonist fenoldopam increased membranous PP 2A activity in WKY but decreased it in SHR. Fenoldopam translocated PP 2A activity from cytosol to the membrane in WKY but not in SHR. We also found that the PP 2A regulatory subunit B56␣ exists in the BBM, where most of the D 1 receptors are located. 43, 44 It is of interest that PP 2A -B56␣ protein level decreased in the BBM from SHR after fenoldopam treatment. The ability of the D 1 -like antagonist to block both the increase in PP 2A activity in WKY and the opposite response in SHR support the notion of an abnormality downstream of the D 1 -like receptor. Because there is no mutation of the D 1 receptor in the SHR, this finding suggests that a primary abnormality of PP 2A -B56␣ may be a cause of the discrepant response of SHR compared with WKY.
Activation of PP 2A necessitates prior phosphorylation of the D 1 -like receptor. [5] [6] [7] [8] 41 Presumably, activation of a G-proteincoupled receptor kinase (GRK) must have occurred after D 1 -like agonist stimulation. The phosphorylation of the D 1 receptor by GRK by GRK2, GRK3, and GRK5 has been reported to play a role in the desensitization of the D 1 receptor. 45 Increased activity and expression of GRK2 has been reported in aortic smooth muscle and lymphocytes from SHR. 46 However, these changes occurred as a consequence of the hypertension. 46 Because the increased phosphorylation of the D 1 receptor in renal proximal tubules is ligand independent, 2, 3, 8, 9, 38 the participation of a constitutively activated GRK must have occurred. The existence of this GRK was not determined in the current studies, but GRK6 has been reported to be constitutively activated. 47 We speculate that a constitutively activated GRK (eg, GRK6) causes basal phosphorylation of D 1 -like receptors in renal proximal tubules in both WKY and SHR. D 1 -like agonist occupation further increases the phosphorylation of renal D 1 -like receptors in WKY but not in SHR. 9 PP 2A dephosphorylates and resensitizes renal D 1 -like receptors in WKY but not in SHR, resulting in a phosphorylated and desensitized D 1 -like receptor in genetic hypertension.
In conclusion, we have demonstrated that after D 1 -like agonist activation, PP 2A activity in renal proximal tubules is increased in WKY but decreased in SHR. We speculate that the increased basal levels of serine-phosphorylated D 1 receptor in RPTC in hypertension may be a consequence of a defect in dephosphorylation of the phosphorylated D 1 receptor. Although we have demonstrated a role of PP 2A in this response, the role of other phosphatases, for example, PP 2B , in the desensitization of D 1 -like receptors in hypertension, remains to be determined. 36 
